Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Novavax Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. Those matters involve 3 distinct examiners and 2 distinct art units, so the portfolio spans more than one examination grouping while maintaining a one-examiner-per-action pattern in the available record. The busiest examiner is FOLEY, SHANON A.
FOLEY, SHANON A. is associated with 1 pending matter, while the remaining activity is distributed among other examiners. Counsel may benefit from matter-specific response planning, with art-unit context treated as a meaningful organizing factor. The data supports tracking examiner assignments separately rather than assuming a single prosecution strategy will apply across the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FOLEY, SHANON A | 1 | 73.3% | +18.2% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| ALLEN, MICHAEL D | 1 | 31.7% | +49.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18828852 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE | FOLEY, SHANON A | — |
| 18645259 | SARS-COV-2 VACCINE COMPOSITIONS | ALLEN, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18828852 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE | FOLEY, SHANON A | 1671 | Other | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18723454 | ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19 | ALAM, DANYAL HASSAN | 1672 | §112 | Non-Final OA | — | Pending | Jun 23, 2024 |
| 18645259 | SARS-COV-2 VACCINE COMPOSITIONS | ALLEN, MICHAEL D | 1671 | §103 | Non-Final OA | — | Pending | Apr 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNovavax Inc. has 3 pending office actions as of November 2026, spread across 2 art units and 3 examiners.
Shanon A Foley has the most, with 1 of Novavax Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.